ClinicalTrials.gg
CompletedNCT01390818Updated Mar 7, 2017Results posted

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of MSC1936369B (pimasertib) and SAR245409 (PI3K and mTOR inhibitor) in Locally Advanced Solid Tumor, Metastatic Solid Tumor and Breast Cancer, sponsored by EMD Serono. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2017-03-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Merck KGaA, Darmstadt, Germany.

Enrollment
8th of 17
146 · median 141
Started
2011
with 1 other
Phase 1
11 of 21
none open now
Registered
13th of 21
by date

Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 1, and was the 13th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

None of the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Neoplasm Metastasis, anywhere →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumors. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Breast Cancer
  • Non Small Cell Lung Cancer
  • Melanoma
  • Colorectal Cancer

Keywords

  • MEK inhibitor (Pimasertib)
  • PI3K/mTOR Inhibitor
  • Solid Tumor
  • Phase I
04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with advanced solid tumors for which there is no approved therapy:

    • Advanced solid tumor with diagnosed alteration in one or more of the following genes (PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 and/or
    • A or cytologically confirmed diagnosis of one of the following solid tumors: pancreatic, thyroid, colorectal, non-small cell lung, endometrial, renal, breast, ovarian carcinoma and melanoma
  • Subject with archived tumor tissue available for transfer to the Sponsor
  • Subject enrolled at lower dose level cohorts and MTD expansion cohorts must have tumor available for and agree to pre-treatment and on-treatment tumor biopsies
  • Subject has measurable or evaluable disease by (RECIST) v1.1
  • Subject is aged greater than or equal to (>=) 18 years
  • Subjects enrolled in disease specific expansion cohorts must fulfill all the inclusion/exclusion criteria listed above with the following restriction to the Inclusion Criterion number 1:

    • Kirsten rat sarcoma viral oncogene homolog (KRAS) or neuroblastoma RAS viral oncogene homolog (NRAS) mutated non-small cell lung cancer (NSCLC) with no approved therapies, or
    • Relapsed or refractory metastatic triple negative breast cancer defined as estrogen, progesterone and negative carcinoma of the breast with no approved therapies, or
    • Relapsed or refractory metastatic colorectal cancer (CRC) with dual KRAS and PIK3CA mutation with no approved therapies, or
    • BRAF V600E/K mutated unresectable or metastatic melanoma after progression on B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors
  • Other protocol-defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Subject has been previously treated with a PI3K inhibitor or a MEK inhibitor and taken off treatment due to treatment related adverse events
  • Subject has received:
  • Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anti-cancer therapy within 28 days of trial drug treatment
  • Any agent within 28 days of trial drug treatment
  • Extensive prior radiotherapy on more than 30% bone marrow reserves, or prior bone marrow/stem cell transplantation
  • Subject has not recovered from toxicity due to prior therapy
  • Subject has poor organ and marrow function as defined in the protocol
  • Subject has a history of central nervous system , unless subject has been previously treated for
  • Subject has a history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease
  • Subject has a history of recent major surgery or trauma within the last 28 days.
  • Subject has participated in another clinical trial within the past 30 days
  • Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    MSC1936369B and SAR245409 once daily

    Drug: MSC1936369B (pimasertib) · Drug: SAR245409 (PI3K and mTOR inhibitor)

  • Experimental
    MSC1936369B and SAR245409 twice daily

    Drug: MSC1936369B (pimasertib) · Drug: SAR245409 (PI3K and mTOR inhibitor)

Interventions

  • MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.

    Also known as: Pimasertib

  • DrugSAR245409 (PI3K and mTOR inhibitor)

    Drug page: XL765

    SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.

    Also known as: PI3K and mTOR inhibitor

  • MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).

    Also known as: pimasertib

  • DrugSAR245409 (PI3K and mTOR inhibitor)

    Drug page: XL765

    SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).

    Also known as: PI3K and mTOR inhibitor

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Dose Limiting Toxicities (DLT)

    DLT was defined as any of the following toxicities experienced during the first cycle of treatment at any dose level (DL) and judged not to be related to the underlying disease or any concomitant medication by the Investigator and/or the Sponsor: A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation (DE) would have exposed subjects to unacceptable risk. Any Grade greater than or equal to (\>=) 3 non-hematological toxicity, except for: Grade 3 diarrhea, nausea and vomiting with a duration less than or equal to (\<=) 48 hours despite adequate supportive care and Alopecia. Grade 4 neutropenia of \> 5 days duration or febrile neutropenia. Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia. Any treatment interruption \> 2 weeks due to AEs not related to the underlying disease or concomitant medication at any dose level and any severe, life-threatening impairing daily functions complication or abnormality.

    Time frame: Day 1 up to Day 16 in cycle 1

Secondary outcomes

  1. Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as those AEs that started between first dose of study drug and up to 30 days after last dose.

    Time frame: Baseline up to 30 Days after last dose; assessed up to 4 years

  2. Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  3. Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  4. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)

    Area under the concentration-time curve from time 0 to the last quantifiable concentration.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1

    Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz).

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts

  6. Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  7. Half-Life (t1/2) of MSC1936369B (Pimasertib)

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  8. Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)

    The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  9. Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  10. Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15

    Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau per Day 1 dosing interval AUCtau.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  11. Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15

    Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax/Day 1 Cmax.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  12. Maximum Observed Plasma Concentration (Cmax) for SAR245409

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  13. Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409

    The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  14. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409

    Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour\*nanogram per milliliter (hr\*ng/mL).

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  15. Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  16. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1

    Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts

  17. Apparent Terminal Half-Life (t1/2) of SAR245409

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  18. Total Body Clearance (CL/f) of SAR245409

    The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the dose with area under the plasma concentration time curve from time zero to infinity (AUC 0-inf)=Dose/AUC 0-inf.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  19. Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  20. Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15

    Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau divided by Day 1 dosing interval AUCtau.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  21. Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15

    Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax divided by Day 1 Cmax.

    Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

  22. pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)

    pS6 Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.

    Time frame: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); Cycle 1 Day 1 (C1D1) and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)

  23. pERK Concentrations in PBMCs

    pERK Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.

    Time frame: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); C1D1 and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)

  24. Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)

    CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From the date of randomisation every 6 weeks up to assessed up to 4 years

07

Results

Posted Mar 7, 2017

Participant flow

First subject (informed consent): May 2011. Study completion date: Apr 2015. A total of 192 subjects were screened and 146 subjects entered the trial and received the investigational medicinal product (IMP).

Participant flow — Overall Study
MilestonePimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once Daily
Started333443191433426241815
Completed333443191433426241815
Not completed000000000000000

Outcome measures

PrimaryNumber of Subjects With Dose Limiting Toxicities (DLT)

DLT was defined as any of the following toxicities experienced during the first cycle of treatment at any dose level (DL) and judged not to be related to the underlying disease or any concomitant medication by the Investigator and/or the Sponsor: A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation (DE) would have exposed subjects to unacceptable risk. Any Grade greater than or equal to (\>=) 3 non-hematological toxicity, except for: Grade 3 diarrhea, nausea and vomiting with a duration less than or equal to (\<=) 48 hours despite adequate supportive care and Alopecia. Grade 4 neutropenia of \> 5 days duration or febrile neutropenia. Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia. Any treatment interruption \> 2 weeks due to AEs not related to the underlying disease or concomitant medication at any dose level and any severe, life-threatening impairing daily functions complication or abnormality.

Time frame:
Day 1 up to Day 16 in cycle 1
Reported as:
Number · subjects
Number of Subjects With Dose Limiting Toxicities (DLT)
subjectsPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily
Number of Subjects With Dose Limiting Toxicities (DLT)00000002121
SecondaryNumber of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as those AEs that started between first dose of study drug and up to 30 days after last dose.

Time frame:
Baseline up to 30 Days after last dose; assessed up to 4 years
Reported as:
Number · subjects
Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)
subjectsPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyMSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once Daily
Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)333443191433426241815
SecondaryMaximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · nanogram/millilitre (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)
nanogram/millilitre (ng/mL)Pimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n=6, 10, 26, 13, 4, 3, 25, 23, 18, 15)86.06 (51.31 to 144.3)188.2 (138.5 to 255.9)246.1 (191.8 to 315.6)406.9 (284.6 to 581.7)83.72 (18.05 to 388.3)232.5 (190.9 to 283.2)323.1 (253.9 to 411.1)295.4 (240.9 to 362.2)245.6 (198.5 to 304.0)234.0 (182.6 to 299.8)
Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 13, 10)131.3 (85.13 to 202.6)212.8 (178.9 to 253.1)234.2 (166.2 to 330.1)516.4 (375.0 to 711.0)143.1 (22.82 to 897.8)NA (NA to NA)320.5 (286.2 to 358.9)327.6 (248.5 to 431.9)307.7 (205.0 to 461.8)338.9 (281.0 to 408.8)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)
hourPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n= 6, 10, 25, 13, 4, 3, 25, 23, 18, 15 )1.750 (0.50 to 2.08)0.765 (0.50 to 2.15)2.020 (0.50 to 8.05)1.500 (0.50 to 3.00)1.485 (0.50 to 2.08)1.550 (0.50 to 2.07)1.500 (0.50 to 7.90)1.520 (0.50 to 7.85)1.490 (0.50 to 4.20)1.050 (0.45 to 4.00)
Day 15 (n= 6, 9, 15, 9, 3, 1, 16, 17, 13, 10)1.275 (0.50 to 3.07)1.000 (1.00 to 1.63)2.000 (1.00 to 7.95)1.550 (1.00 to 2.00)2.000 (1.50 to 4.17)NA (NA to NA)1.505 (0.53 to 3.00)1.530 (1.00 to 4.00)1.500 (0.50 to 8.00)1.030 (0.48 to 3.83)
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)

Area under the concentration-time curve from time 0 to the last quantifiable concentration.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · hour*nanogram per millilitre (hr*ng/mL)
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)
hour*nanogram per millilitre (hr*ng/mL)Pimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n=6, 10, 25, 13, 4, 3, 25, 23, 18, 15)426.8 (306.2 to 594.9)734.4 (586.1 to 920.3)1547 (1238 to 1934)2116 (1664 to 2692)326.1 (110.9 to 958.7)1252 (1100 to 1425)1781 (1404 to 2260)1754 (1480 to 2078)1709 (1361 to 2146)1093 (871.5 to 1371)
Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 10, 13)625.3 (405.7 to 963.9)902.0 (747.6 to 1088)1617 (1170 to 2236)2552 (2185 to 2980)773.1 (201.0 to 2974)NA (NA to NA)2136 (1713 to 2663)1889 (1540 to 2318)1988 (1487 to 2658)1506 (1141 to 1988)
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1

Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz).

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1
hr*ng/mLPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1451.6 (319.8 to 637.8)770.9 (599.9 to 990.6)1607 (1237 to 2087)2202 (1716 to 2826)503.1 (153.1 to 1654)—1869 (1451 to 2407)1830 (1518 to 2207)1857 (1414 to 2437)1113 (858.9 to 1442)
SecondaryArea Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)
hr*ng/mLPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n= 6, 10, 26, 13, 3, 3, 24, 23, 17,13)426.8 (306.2 to 594.9)742.1 (602.0 to 914.7)1547 (1238 to 1934)2116 (1664 to 2692)354.9 (48.21 to 2613)1252 (1100 to 1425)1882 (1513 to 2341)1754 (1480 to 2078)1772 (1409 to 2227)1093 (871.5 to 1371)
Day 15 (n=6, 9, 15, 9, 3, 0, 16, 17, 10, 13)650.4 (440.1 to 961.2)902.0 (747.6 to 1088)1617 (1170 to 2236)2552 (2185 to 2980)773.1 (201.0 to 2974)NA (NA to NA)2136 (1713 to 2663)1889 (1540 to 2318)1988 (1487 to 2658)1506 (1141 to 1988)
SecondaryHalf-Life (t1/2) of MSC1936369B (Pimasertib)
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Median · hour
Half-Life (t1/2) of MSC1936369B (Pimasertib)
hourPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n=6, 9, 23, 13, 4, 3, 22, 22, 15, 13)6.250 (5.03 to 7.16)4.670 (1.85 to 5.79)4.840 (3.23 to 9.99)4.800 (3.49 to 7.62)3.320 (2.60 to 4.72)4.640 (4.25 to 4.74)4.840 (2.46 to 8.41)4.370 (3.71 to 8.26)4.770 (3.51 to 12.8)4.240 (3.32 to 4.84)
Day 15 (n=6, 9, 14, 9, 2, 1, 16, 16, 9, 12)5.855 (2.93 to 7.88)5.410 (3.90 to 10.8)6.755 (4.61 to 14.3)5.590 (3.97 to 14.1)NA (NA to NA)NA (NA to NA)5.210 (3.25 to 12.8)5.250 (4.33 to 8.65)5.210 (4.80 to 6.94)4.325 (3.40 to 5.96)
SecondaryTotal Body Clearance (CL/f) of Pimasertib (MSC1936369B)

The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · litre per hour (L/hr)
Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)
litre per hour (L/hr)Pimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n=6, 10, 26, 13, 3, 0, 22, 22, 14, 13)33.22 (23.52 to 46.92)38.90 (30.26 to 50.00)37.99 (29.33 to 49.22)40.88 (31.85 to 52.47)89.49 (27.14 to 295.1)NA (NA to NA)32.12 (24.95 to 41.36)32.75 (27.16 to 39.50)30.75 (23.41 to 40.41)53.94 (41.61 to 69.62)
Day 15 (n=6, 9, 15, 9, 3, 1, 16, 17, 10, 13)23.06 (15.59 to 34.10)33.30 (27.63 to 40.13)37.11 (26.82 to 51.33)35.28 (30.19 to 41.23)58.22 (15.03 to 225.6)NA (NA to NA)28.11 (22.54 to 35.07)31.73 (25.85 to 38.94)30.20 (22.59 to 40.38)39.81 (30.17 to 52.52)
SecondaryApparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · liter
Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib
literPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Day 1 (n=6, 9, 23, 13, 3, 0, 22, 22, 14, 13)294.3 (218.5 to 396.4)240.2 (202.5 to 284.9)282.8 (227.7 to 351.4)283.0 (224.0 to 357.6)394.1 (146.9 to 1058)—223.8 (182.7 to 274.3)226.9 (193.9 to 265.4)216.2 (174.6 to 267.8)322.0 (251.5 to 412.3)
Day 15 (n=6, 9, 13, 9, 0, 0, 16, 16, 9, 12)188.7 (133.4 to 266.9)261.8 (187.9 to 364.8)396.4 (276.9 to 567.3)302.4 (223.1 to 409.7)NA (NA to NA)—226.3 (189.7 to 270.1)250.9 (214.2 to 293.9)230.6 (169.0 to 314.6)273.8 (213.8 to 350.7)
SecondaryAccumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15

Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau per Day 1 dosing interval AUCtau.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · ratio
Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15
ratioPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 151.523 (1.295 to 1.792)1.269 (1.107 to 1.455)1.174 (0.9326 to 1.479)1.364 (1.133 to 1.642)2.176 (0.1184 to 39.99)NA (NA to NA)1.368 (1.044 to 1.792)1.155 (1.004 to 1.330)1.245 (0.9538 to 1.625)1.283 (1.104 to 1.490)
SecondaryAccumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15

Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax/Day 1 Cmax.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · ratio
Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15
ratioPimasertib (MSC1936369B) 15mgPimasertib (MSC1936369B) 30mgPimasertib (MSC1936369B) 60mgPimasertib (MSC1936369B) 90mgPimasertib (MSC1936369B) 45mg Twice DailyPimasertib (MSC1936369B) 60mg Twice DailyTNBC: Pimasertib 60mg Once DailyNSCLC: Pimasertib 60mg Once DailyCRC: Pimasertib 60mg Once DailyMEL: Pimasertib 60mg Once Daily
Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 151.525 (1.002 to 2.322)1.066 (0.7442 to 1.527)1.106 (0.7904 to 1.546)1.308 (0.7537 to 2.268)1.467 (0.02541 to 84.67)NA (NA to NA)1.203 (0.9074 to 1.595)1.059 (0.8875 to 1.263)1.247 (0.8719 to 1.784)1.393 (1.091 to 1.780)
SecondaryMaximum Observed Plasma Concentration (Cmax) for SAR245409
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for SAR245409
nanogram per millilitre (ng/mL)SAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg OnceCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)192.0 (115.6 to 316.3)295.7 (189.0 to 462.6)256.9 (203.5 to 324.3)224.5 (99.72 to 505.2)130.2 (20.76 to 816.5)64.22 (19.25 to 214.2)323.6 (258.4 to 405.2)240.6 (164.6 to 351.6)239.6 (158.8 to 361.4)212.5 (129.3 to 349.4)
Day 15 (n=6, 6, 25, 1, 1, 3, 17, 17, 10, 13)199.8 (114.4 to 349.1)224.1 (132.7 to 378.4)222.9 (143.7 to 345.7)NA (NA to NA)NA (NA to NA)117.2 (7.210 to 1907)326.0 (256.4 to 414.6)235.5 (144.6 to 383.3)178.9 (82.31 to 389.0)226.6 (143.9 to 356.7)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of SAR245409

The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409
hoursSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)1.510 (0.53 to 2.08)1.150 (0.50 to 4.10)1.500 (0.50 to 23.80)1.500 (1.00 to 8.00)2.050 (1.50 to 2.07)1.540 (0.50 to 4.00)1.500 (0.52 to 8.03)2.000 (0.50 to 4.17)2.000 (0.43 to 8.05)1.500 (0.95 to 4.00)
Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)1.265 (1.00 to 2.00)1.750 (0.53 to 3.00)1.970 (1.00 to 8.13)NA (NA to NA)NA (NA to NA)1.550 (1.50 to 8.00)2.030 (0.52 to 7.98)1.530 (0.92 to 8.00)1.750 (0.50 to 8.00)1.050 (0.50 to 3.97)
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409

Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour\*nanogram per milliliter (hr\*ng/mL).

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409
hr*ng/mLSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)683.6 (248.9 to 1878)1248 (760.1 to 2050)1566 (1162 to 2111)3032 (1425 to 6454)634.0 (111.8 to 3595)226.2 (82.99 to 616.7)1976 (1449 to 2693)1408 (962.5 to 2059)1479 (824.6 to 2653)854.9 (505.0 to 1447)
Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)861.0 (371.5 to 1995)1125 (558.3 to 2266)1334 (895.8 to 1986)NA (NA to NA)NA (NA to NA)537.5 (56.10 to 5150)2232 (1512 to 3297)1437 (922.1 to 2239)1365 (543.4 to 3431)968.8 (554.8 to 1692)
SecondaryArea Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409
hr*ng/mLSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=6, 11, 36, 3, 3, 3, 24, 23, 17, 15)746.9 (275.5 to 2024)1265 (784.5 to 2041)1601 (1195 to 2145)3032 (1425 to 6454)634.0 (111.8 to 3595)298.6 (120.4 to 740.6)2115 (1535 to 2915)1480 (1026 to 2137)1542 (851.5 to 2792)948.4 (601.8 to 1495)
Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)887.9 (397.9 to 1981)1168 (611.5 to 2232)1362 (918.9 to 2018)NA (NA to NA)NA (NA to NA)537.5 (56.10 to 5150)2390 (1696 to 3368)1437 (922.1 to 2239)1365 (543.4 to 3431)1074 (636.9 to 1811)
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1

Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1
hr*ng/mLSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1716.5 (181.8 to 2823)1165 (648.3 to 2093)1504 (1113 to 2034)NA (NA to NA)NA (NA to NA)331.2 (151.5 to 724.1)1974 (1408 to 2768)1445 (1019 to 2049)1261 (579.4 to 2743)1142 (750.4 to 1739)
SecondaryApparent Terminal Half-Life (t1/2) of SAR245409
Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Median · hour
Apparent Terminal Half-Life (t1/2) of SAR245409
hourSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=6, 9, 31, 2, 2, 3, 20, 19, 13, 14)3.055 (1.78 to 7.57)3.300 (1.45 to 8.94)3.390 (0.964 to 9.28)NA (NA to NA)NA (NA to NA)3.310 (2.47 to 3.37)3.755 (1.32 to 7.59)3.300 (2.54 to 27.9)4.070 (2.14 to 9.02)3.120 (1.32 to 6.03)
Day 15 (n=6, 8, 22, 1, 1, 2, 10, 15, 8, 10)3.700 (2.07 to 5.60)4.570 (1.81 to 6.49)4.560 (2.37 to 35.2)NA (NA to NA)NA (NA to NA)NA (NA to NA)2.840 (1.48 to 5.63)4.050 (2.74 to 7.87)6.170 (3.43 to 11.8)3.065 (1.79 to 5.37)
SecondaryTotal Body Clearance (CL/f) of SAR245409

The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the dose with area under the plasma concentration time curve from time zero to infinity (AUC 0-inf)=Dose/AUC 0-inf.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · litre per hour
Total Body Clearance (CL/f) of SAR245409
litre per hourSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12)41.80 (10.62 to 164.5)42.93 (23.89 to 77.16)46.54 (34.42 to 62.94)NA (NA to NA)NA (NA to NA)151.4 (69.37 to 330.4)35.43 (25.26 to 49.69)48.40 (34.12 to 68.64)55.51 (25.52 to 120.7)61.29 (40.26 to 93.30)
Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)33.78 (15.16 to 75.26)42.81 (22.39 to 81.85)51.38 (34.68 to 76.13)NA (NA to NA)NA (NA to NA)92.90 (9.667 to 892.8)29.28 (20.78 to 41.26)48.69 (31.25 to 75.88)51.24 (20.38 to 128.8)65.16 (38.64 to 109.9)
SecondaryApparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · litre
Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)
litreSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12)174.8 (71.24 to 429.0)223.4 (116.2 to 429.6)238.5 (179.0 to 317.8)NA (NA to NA)NA (NA to NA)658.0 (211.9 to 2044)175.2 (123.9 to 247.9)251.4 (158.4 to 398.9)353.6 (177.1 to 705.8)270.3 (175.6 to 416.0)
Day 15 (n=6, 8, 25, 1, 1, 2, 17, 17, 10, 13 )165.7 (99.48 to 276.1)257.2 (156.7 to 422.1)355.9 (212.5 to 596.2)NA (NA to NA)NA (NA to NA)NA (NA to NA)132.8 (96.16 to 183.4)247.1 (149.4 to 410.7)475.9 (128.0 to 1769)293.4 (141.6 to 607.7)
SecondaryAccumulation Ratio (Racc) for AUCtau of SAR245409: Day 15

Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau divided by Day 1 dosing interval AUCtau.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · ratio
Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15
ratioSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 151.189 (0.6118 to 2.311)1.004 (0.4637 to 2.175)0.9450 (0.6749 to 1.323)NA (NA to NA)NA (NA to NA)1.800 (0.1724 to 18.79)1.256 (0.9407 to 1.676)0.9887 (0.7202 to 1.357)1.187 (0.7614 to 1.850)1.022 (0.6346 to 1.645)
SecondaryAccumulation Ratio (Racc) for Cmax of SAR245409: Day 15

Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax divided by Day 1 Cmax.

Time frame:
Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Reported as:
Geometric mean · Ratio
Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15
RatioSAR245409 30mgSAR245409 50mgSAR245409 70mgSAR245409 90mgSAR245409 30mg Twice DailySAR245409 50mg Twice DailyTNBC: SAR245409 70mg Once DailyNSCLC: SAR245409 70mg Once DailyCRC: SAR245409 70mg Once DailyMEL: SAR245409 70mg Once Daily
Accumulation Ratio (Racc) for Cmax of SAR245409: Day 151.041 (0.6293 to 1.722)0.8133 (0.3484 to 1.898)0.8962 (0.6151 to 1.306)NA (NA to NA)NA (NA to NA)1.336 (0.03347 to 53.32)1.070 (0.8319 to 1.375)0.8950 (0.6951 to 1.152)0.9611 (0.6441 to 1.434)0.9942 (0.5447 to 1.815)
SecondarypS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)

pS6 Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.

Time frame:
DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); Cycle 1 Day 1 (C1D1) and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)
Reported as:
Mean · fluorescence intensity
pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)
fluorescence intensityPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily
DDI Day 1: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)61.02 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA33.78 ± NA
DDI Day 1: 2hr post-dose (n= 1,0,0,0,0,0,1)36.15 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA29.84 ± NA
DDI Day 1: 4hr post-dose (n= 1,0,0,0,0,0,1)89.14 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA30.28 ± NA
DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)54.54 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA44.88 ± NA
DDI Day 1: 24hr post-dose (n= 1,0,0,0,0,0,0)88.80 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
DDI Day 2: 24hr post-dose (n= 0,0,0,0,0,0,1)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA28.86 ± NA
DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)57.51 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA14.90 ± NA
DDI Day 3: 2hr post-dose (n= 1,0,0,0,0,0,1)55.93 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA34.06 ± NA
DDI Day 3: 4hr post-dose (n= 1,0,0,0,0,0,1)36.76 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA1.03 ± NA
DDI: Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)1.08 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA40.40 ± NA
DDI:Day 3: 24hr post-dose (n= 1,0,0,0,0,0,0)87.60 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
DDI Day 4: 24hr post-dose (n= 0,0,0,0,0,0,1)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA1.04 ± NA
C1D1: Pre dose (n= 1,1,1,1,1,1,1)51.32 ± NA83.52 ± NA96.98 ± NA47.09 ± NA50.17 ± NA4.18 ± NA36.03 ± NA
C1D1: 2hr postdose (n= 1,1,1,1,1,1,1)31.08 ± NA24.48 ± NA56.41 ± NA23.89 ± NA5.72 ± NA0.92 ± NA1.04 ± NA
C1D1: 4hr postdose (n= 1,1,1,1,1,1,1)25.71 ± NA46.95 ± NA50.11 ± NA29.85 ± NA18.21 ± NA0.72 ± NA0.94 ± NA
C1D1: 8hr postdose (n= 1,1,1,1,1,1,1)3.02 ± NA1.28 ± NA84.57 ± NA19.75 ± NA6.21 ± NA1.18 ± NA0.96 ± NA
C1D1: 24hr postdose(n= 1,1,1,1,0,0,0)46.16 ± NA72.14 ± NA74.15 ± NA53.47 ± NANA ± NANA ± NANA ± NA
C1D2: 24hr postdose (n= 0,0,0,0,1,1,1)NA ± NANA ± NANA ± NANA ± NA24.66 ± NA1.61 ± NA1.00 ± NA
C1D15: pre-dose (n= 1,1,1,1,1,0,1)43.48 ± NA81.29 ± NA67.69 ± NA1.20 ± NA33.43 ± NANA ± NA0.98 ± NA
C1D15: 2hr postdose (n= 1,1,1,1,1,0,1)26.41 ± NA43.70 ± NA48.23 ± NA15.02 ± NA21.11 ± NANA ± NA1.06 ± NA
C1D15: 4hr postdose (n= 1,1,1,1,1,0,1)41.34 ± NA53.37 ± NA92.67 ± NA0.96 ± NA19.68 ± NANA ± NA1.03 ± NA
C1D15: 8hr postdose (n= 1,1,1,1,1,0,1)0.53 ± NA45.97 ± NA77.62 ± NA36.06 ± NA30.08 ± NANA ± NA0.88 ± NA
C1D15: 24hr postdose (n= 1,1,1,1,0,0,0)69.93 ± NA0.76 ± NA114.39 ± NA70.46 ± NANA ± NANA ± NANA ± NA
C1D16: 24hr postdose (n= 0,0,0,0,1,0,1)NA ± NANA ± NANA ± NANA ± NA24.36 ± NANA ± NA0.98 ± NA
C1D19: pre-dose (n= 1,1,1,1,1,0,1)68.48 ± NA90.02 ± NA125.77 ± NA82.06 ± NA30.58 ± NANA ± NA49.62 ± NA
C1D19: 2hr postdose (n= 1,0,0,0,0,0,0)4.34 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondarypERK Concentrations in PBMCs

pERK Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.

Time frame:
DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); C1D1 and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)
Reported as:
Mean · fluorescence intensity
pERK Concentrations in PBMCs
fluorescence intensityPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily
DDI Day 1: Predose (n= 1, 0, 0, 0, 0, 0, 1)6.77 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA10.55 ± NA
DDI Day 1: 2 hr post-dose (n=1,0,0,0,0.0,1)8.74 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA10.17 ± NA
DDI Day 1: 4 hr post-dose ((n=1,0,0,0,0,0,1)6.10 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA6.50 ± NA
DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)7.42 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA9.36 ± NA
DDI Day 1: 24 hr post-dose (n=1,0,0,0,0,0,0)10.84 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
DDI Day 2: 24 hr post-dose ((n= 0,0,0,0,0,0,1)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA8.32 ± NA
DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)9.46 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA8.94 ± NA
DDI Day 3: 2 hr post-dose (n=1,0,0,0,0,0,1)3.12 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA15.82 ± NA
DDI Day 3: 4 hr post-dose (n-1,0,0,0,0,0,1)6.74 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA0.68 ± NA
DDI Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)0.81 ± NANA ± NANA ± NANA ± NANA ± NANA ± NA15.68 ± NA
DDI Day 3: 24 hr post-dose (n=1,0,0,0,0,0,0)6.18 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
DDI Day 4: 24 hr post-dose (n=0,0,0,0,0,0,1)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA1.06 ± NA
C1D1: Pre dose (n=1,1,1,1,1,1,1)5.56 ± NA3.45 ± NA6.96 ± NA3.25 ± NA3.35 ± NA1.97 ± NA7.42 ± NA
C1D1: 2hr postdose(n= 1,1,1,1,1,1,1)2.37 ± NA1.33 ± NA2.78 ± NA1.54 ± NA1.40 ± NA0.95 ± NA1.04 ± NA
C1D1: 4hr postdose(n= 1,1,1,1,1,1,1)2.85 ± NA1.37 ± NA2.91 ± NA1.24 ± NA1.96 ± NA1.11 ± NA1.01 ± NA
C1D1: 8hr postdose(n= 1,1,1,1,1,1,1)0.67 ± NA0.94 ± NA3.40 ± NA1.96 ± NA1.27 ± NA1.12 ± NA0.82 ± NA
C1D1: 24hr postdose(n= 1,1,1,1,0,0,0)6.23 ± NA2.15 ± NA4.59 ± NA6.26 ± NANA ± NANA ± NANA ± NA
C1D2: 24hr postdose(n= 0,0,0,0,1,1,1)NA ± NANA ± NANA ± NANA ± NA3.45 ± NA1.26 ± NA1.05 ± NA
C1D15: pre-dose(n= 1,1,1,1,1,0,1)3.79 ± NA2.26 ± NA5.29 ± NA1.41 ± NA1.93 ± NANA ± NA2.03 ± NA
C1D15: 2hr postdose (n= 1,1,1,1,1,0,1)2.16 ± NA1.34 ± NA2.83 ± NA1.60 ± NA1.55 ± NANA ± NA0.94 ± NA
C1D15: 4hr postdose (n= 1,1,1,1,1,0,1)1.87 ± NA1.34 ± NA2.50 ± NA0.94 ± NA1.20 ± NANA ± NA0.81 ± NA
C1D15: 8hr postdose (n= 1,1,1,1,1,0,1)1.92 ± NA2.08 ± NA3.38 ± NA1.10 ± NA1.74 ± NANA ± NA0.99 ± NA
C1D15: 24hr postdose (n= 1,1,1,1,0,0,0)4.97 ± NA0.94 ± NA5.33 ± NA4.70 ± NANA ± NANA ± NANA ± NA
C1D16: 24hr postdose (n= 0,0,0,0,1,0,1)NA ± NANA ± NANA ± NANA ± NA2.36 ± NANA ± NA0.99 ± NA
C1D19: pre-dose (n= 1,1,1,1,1,0,1)6.54 ± NA2.61 ± NA4.47 ± NA5.44 ± NA2.07 ± NANA ± NA5.72 ± NA
C1D19: 2hr postdose (n= 1,0,0,0,0,0,0)1.60 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryNumber of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)

CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From the date of randomisation every 6 weeks up to assessed up to 4 years
Reported as:
Number · subjects
Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)
subjectsPimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once Daily
Stable disease3223124601271017
Progressive disease001110932018694
Complete Response000000000000001
Partial Response010000020000101
Not Evaluable000020000001311

Adverse events

Collected over Baseline up to 30 Days after last dose; assessed up to 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once Daily—1/3 (33.3%)3/3 (100%)
MSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once Daily—0/3 (0%)3/3 (100%)
MSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once Daily—2/3 (66.7%)3/3 (100%)
MSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once Daily—1/4 (25%)4/4 (100%)
MSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once Daily—1/4 (25%)4/4 (100%)
MSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once Daily—1/3 (33.3%)3/3 (100%)
MSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once Daily—14/19 (73.7%)19/19 (100%)
MSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once Daily—10/14 (71.4%)14/14 (100%)
MSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once Daily—1/3 (33.3%)3/3 (100%)
MSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice Daily—2/3 (66.7%)3/3 (100%)
MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily—3/4 (75%)4/4 (100%)
TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily—16/26 (61.5%)26/26 (100%)
NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily—13/24 (54.2%)24/24 (100%)
CRC: Pimasertib 60mg and SAR245409 70mg Once Daily—10/18 (55.6%)18/18 (100%)
MEL: Pimasertib 60mg and SAR245409 70mg Once Daily—8/15 (53.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventMSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once DailyMSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice DailyMSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once Daily
DIARRHOEAGastrointestinal disorders0/30/30/30/40/40/31/190/140/30/32/40/260/242/180/15
DISEASE PROGRESSIONGeneral disorders1/30/30/30/40/40/34/191/140/30/32/41/263/242/180/15
NAUSEAGastrointestinal disorders0/30/30/30/40/40/31/191/141/30/31/40/261/242/180/15
VOMITINGGastrointestinal disorders0/30/30/30/40/40/31/190/141/30/31/40/260/242/181/15
DYSPHAGIAGastrointestinal disorders0/30/31/30/40/40/30/190/140/30/30/40/261/240/180/15
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/30/30/30/40/41/30/190/140/30/31/40/260/240/180/15
PYREXIAGeneral disorders0/30/30/30/40/40/34/193/140/31/31/42/261/242/180/15
CELLULITISInfections and infestations0/30/31/30/40/40/30/190/140/30/30/41/260/240/181/15
HYPONATRAEMIAMetabolism and nutrition disorders0/30/30/30/40/40/31/191/141/30/30/41/260/241/180/15
HYPOGLYCAEMIAMetabolism and nutrition disorders0/30/31/30/40/40/30/190/140/30/30/40/260/240/180/15
Most frequent other events
Showing 10 of 371
Most frequent other events
EventMSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once DailyMSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once DailyMSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once DailyMSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice DailyMSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once Daily
DIARRHOEAGastrointestinal disorders3/32/32/34/42/42/310/1913/141/33/31/422/2619/2413/1810/15
NAUSEAGastrointestinal disorders1/32/32/31/41/43/37/198/142/33/30/411/2615/248/187/15
VOMITINGGastrointestinal disorders1/31/30/30/42/43/38/199/141/32/33/412/2611/247/188/15
FATIGUEGeneral disorders3/31/32/32/43/42/38/199/142/33/34/417/2614/249/184/15
OEDEMA PERIPHERALGeneral disorders1/32/33/31/41/40/37/197/141/32/31/47/265/243/184/15
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders3/32/30/32/40/42/39/196/141/32/31/413/268/244/187/15
HYPERTENSIONSkin and subcutaneous tissue disorders1/30/30/30/40/40/33/190/143/30/31/43/263/241/185/15
COUGHRespiratory, thoracic and mediastinal disorders1/30/30/31/43/40/31/192/140/31/30/43/264/242/181/15
RASH MACULO-PAPULARSkin and subcutaneous tissue disorders1/31/30/32/43/40/36/195/141/32/33/46/2612/244/185/15
ANAEMIABlood and lymphatic system disorders1/30/32/31/41/40/37/193/141/30/30/44/262/244/180/15

Baseline characteristics

The Safety analysis set (SAF) included subjects who received at least one (non-zero) administration of the trial IMPs (pimasertib and/or SAR245409).

Age, Categorical
Age, Categorical(Participants)Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once DailyTotal
<=18 years0000000000000000
Between 18 and 65 years211212161232222161213107
>=65 years12223132012486239
Gender
Gender(Participants)Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyPimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyPimasertib (MSC1936369B) 30mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 90mg and SAR245409 70mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 90mg Once DailyPimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice DailyPimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice DailyTNBC: Pimasertib 60mg and SAR245409 70mg Once DailyNSCLC: Pimasertib 60mg and SAR245409 70mg Once DailyCRC: Pimasertib 60mg and SAR245409 70mg Once DailyMEL: Pimasertib 60mg and SAR245409 70mg Once DailyTotal
Female312111613120261511487
Male0213321312140971159
08

Study locations

8 sites
  • Pinnacle Oncology Hematology
    Scottsdale, Arizona 85258, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37205, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 78229, United States
  • Merck Serono Research Site
    Milan, Italy
  • Merck Serono Research Site
    Madrid, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2011
First posted
Jul 11, 2011
Start
May 2011
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Mar 7, 2017
Last update
Mar 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01390818
Lead sponsor
EMD Serono
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jul 11, 2011
Start date
May 2011
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Mar 7, 2017
Last update
Mar 7, 2017

Study contacts

Medical Responsible
study director · EMD Serono, a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pimasertib · XL765

Start the discussion